A trial can exaggerate treatment benefit when its comparator removes established therapy.
Measure both heart rate and blood pressure through ten minutes of standing; an isolated fast heart rate does not establish postural orthostatic tachycardia syndrome.
Claims that triple inhaler therapy reduces mortality in chronic obstructive pulmonary disease sound decisive. The difficulty is that around 80% of participants in the ETHOS and IMPACT trials were already taking maintenance inhaled corticosteroids before randomisation.
Allocation to dual bronchodilator therapy reduced inhaled corticosteroid use from about 80% to none. Allocation to triple therapy increased it to 100%. The comparison therefore did not simply test whether starting an inhaled corticosteroid improves survival. It also tested what happens when established treatment is withdrawn.
In ETHOS, overall mortality was 1.4% with triple therapy and 2.6% with dual therapy. Among participants who had previously used inhaled corticosteroids, mortality was 3.0% after withdrawal and 1.3% when treatment continued as part of triple therapy. Among previous non-users, introducing an inhaled corticosteroid did not produce a statistically significant mortality difference.
I would be cautious about turning those figures into a claim that starting triple therapy reduces deaths. The pattern is compatible with harm from withdrawing established inhaled corticosteroids from the comparator group. Mortality was also a secondary endpoint. That does not make the trial irrelevant. It narrows the mortality claim that can reasonably be made.
The design problem is easy to miss when a comparator arm removes established treatment. Reading only the therapies assigned after randomisation will not reveal it. A simple before-and-after map for each arm makes the issue visible: what did participants arrive taking, what was stopped, and what was started?
Single-inhaler triple therapy can still be judged on exacerbation outcomes, safety, cost and convenience. Those questions should be kept separate from an uncertain mortality claim. Guidelines and formulary decisions need the same discipline when a headline result may be driven by how the control group was treated.
For patients, the consequence is practical. Before withdrawing maintenance inhaled corticosteroids from someone with COPD, establish why they were started and review the exacerbation history. Respiratory deterioration after an inhaler change should prompt review of what was withdrawn, not only what replaced it. When the balance remains uncertain, seek patient-specific respiratory review. A mortality headline should not substitute for understanding what treatment is already being taken and what may happen when it is removed.
Most participants in ETHOS and IMPACT already used inhaled corticosteroids, so the dual-therapy comparator withdrew established treatment. Reanalysis suggests the mortality difference may reflect withdrawal harm rather than proof that starting triple therapy reduces deaths.
Adrenal incidentalomas, haemorrhagic masses, suspected adrenocortical carcinoma and retroperitoneal paraganglioma require biochemical localisation, review of older imaging and careful operative planning. Timing, tumour handling, vascular control and referral depend on stability, anatomy and surgical expertise.
Focused cardiac ultrasound may reveal ventricular fibrillation despite a monitor showing pulseless electrical activity or asystole. A convincing finding during a planned pulse check identifies a potentially shockable rhythm and can prompt defibrillation.
Chronic symptoms that worsen upright and improve supine should prompt structured heart-rate and blood-pressure measurement through ten minutes of standing. Diagnosis also requires exclusion of mimics, while treatment begins with volume expansion, compression and recumbent exercise.
Inherited metabolic care in Azerbaijan combines newborn screening with expanding diagnostics and multidisciplinary support, but specialist access remains uneven. Rare cases illustrate clues to Allan-Herndon-Dudley syndrome and TEFM-related mitochondrial disease when neurodevelopmental and movement phenotypes do not fit.
Cause-directed treatment for infantile epilepsy depends on whether the underlying problem is genetic or structural. Seizure freedom remains important, but developmental, cognitive and behavioural outcomes require long-term follow-up and should shape treatment evaluation.
Unexpected hyperkalaemia should be confirmed before treatment is changed, with attention to haemolysis, kidney function, medicines, acidosis and constipation. Hypokalaemia assessment uses urine potassium and magnesium, while management aims to preserve beneficial cardiorenal therapy where possible.
Before accepting a mortality claim, map each trial arm’s treatment before randomisation and after allocation. Check whether the comparator removes established therapy and whether mortality is a secondary endpoint. Before withdrawing inhaled corticosteroids from a patient with COPD, review why they were started and the previous exacerbation history.
A COPD trial enrols a population in which around 80% already use maintenance inhaled corticosteroids. Randomisation removes them in the dual-therapy arm and continues them in the triple-therapy arm. Mortality is lower with triple therapy. What is the most defensible interpretation?
The difference may reflect harm from corticosteroid withdrawal rather than a mortality benefit from starting triple therapy. Previous treatment, subgroup findings and the fact that mortality is a secondary endpoint must be considered.
During cardiac arrest, the monitor shows pulseless electrical activity, but focused cardiac ultrasound during a planned pulse check convincingly shows myocardial fibrillation. What action should follow?
Treat the ultrasound finding as ventricular fibrillation and proceed to defibrillation. Reconcile the monitor and ultrasound appearances rather than assuming the displayed rhythm excludes a shockable rhythm.
An adult with hypokalaemia receives repeated potassium replacement, but the potassium remains low. Testing shows hypomagnesaemia. What should management prioritise?
Correct the magnesium deficiency and identify its cause. Hypomagnesaemia promotes renal potassium wasting and can prevent sustained correction of hypokalaemia.
.svg)